bioAffinity Technologies, Inc. (BIAF)

0.0000 0.0000 (0.00%) At close: 08:00PM EDT

bioAffinity Technologies, Inc.

22211 West Interstate 10
Suite 1206
San Antonio, TX 78257
United States
210 698 5334
https://www.bioaffinitytech.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 11

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Maria Zannes J.D.	Founder, Pres, CEO & Director	227.2k	N/A	1956
Dr. Vivienne I. Rebel M.D., Ph.D.	Exec. VP and Chief Medical & Science Officer	236.59k	N/A	1965
Mr. Michael Edwards CPA, M.B.A.	Chief Financial Officer	N/A	N/A	1967
Mr. Xavier T. Reveles M.S.	VP of Operations	N/A	N/A	N/A
Mr. Timothy P. Zannes J.D.	Exec. VP, Sec. & Gen. Counsel	N/A	N/A	1953
Dr. William Bauta Ph.D.	Sr. VP of R&D - Therapeutics	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Corporate Governance

bioAffinity Technologies, Inc. ’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.